Category Archives: Industry: Healthcare

Healthcare is an ever evolving industry, and field. These Press Releases, will keep you up to date on the newest, greatest, best, solutions available.

JumpMind Expands Database Support with SymmetricDS Pro 3.11


SymmetricDS Pro Database Replication

SymmetricDS Pro replicates Oracle, SAP HANA, and 20+ other database platforms.

Building on our strength of flexibility, we’ve extended our architecture to include log-based data replication.

JumpMind, a leading provider of data integration software, announces the availability of SymmetricDS Pro version 3.11, database replication software with cross-platform support for more than 20 databases. This release includes log-based data replication for Oracle, adds SAP HANA as a source or target, and improves the performance of subsetting large data sets.

Oracle users can now choose between log-based or trigger-based capture of data. Log-based data replication can be beneficial for reducing overhead by processing the logs asynchronously outside of the database in a continuous mode. With either option, the same powerful set of features are available, including vertical and horizontal subsetting, filtering, conflict management, and data transformation. “Building on our strength of flexibility, we’ve extended our architecture to include log-based data replication, which will benefit our users with batch-oriented, high throughput requirements,” said Eric Long, Vice President of Solutions.

SymmetricDS expands its support of cloud-based, analytical databases with the addition of the SAP HANA database. Data can be securely replicated across on-premise, hybrid cloud, and multi-cloud environments to propagate changes into HANA or receive changes from it. Consolidate data in real-time from multiple sources into HANA and leverage its fast analytics, OLAP, and OLTP operations. SymmetricDS enables continuous data replication with features like guaranteed data delivery, filtered synchronization, and wide area network optimization.

Subsetting data to groups of databases now gains performance from common batches that are shared by multiple targets. Common batches were previously used when routing to all targets, but now any arbitrary group is supported, such as databases by region, district, or business unit. When changes are routed to databases across thousands of locations, the reduction in replication time can be dramatic. “We help customers scale out to thousands of databases. As the complexity of slicing and dicing data has increased, we’ve enhanced common batches to handle that load,” said Long.

About JumpMind

JumpMind is an open source software company specializing in data integration and database replication software for the enterprise. We help companies build integration solutions that combine data from disparate sources into meaningful and valuable information. Our mission is to build software that is effective, open, and easy to use. We provide consulting, training, and support for our software products. See how JumpMind solves data integration by visiting http://www.JumpMind.com.

Share article on social media or email:

Heart to Heart Hospice among Those Providing Highest Level of Quality


News Image

“Based on feedback from caregivers themselves, Hospice Honors recognizes agencies that truly stand out.”

As National Hospice and Palliative Care Month is recognized during November, Heart to Heart Hospice celebrates being named among those providing the highest quality of hospice care.

Four Heart to Heart Hospice Texas locations have been named by HEALTHCAREfirst as 2019 Hospice Honors recipients: East Texas (Longview), San Antonio, and San Marcos.

The Tyler, Texas, location earned the special recognition of Hospice Honors Elite.

HEALTHCAREfirst is a leading provider of billing and coding services, CAHPS (Consumer Assessment of Healthcare Providers and Systems) surveys, and advanced analytics. Their Hospice Honors is a prestigious program that recognizes hospices providing the highest level of quality as measured from the caregivers’ point of view.

“Based on feedback from caregivers themselves, Hospice Honors recognizes agencies that truly stand out, based on the level of hospice care and ongoing commitment displayed to their patients and their caregivers,” said Misty Skinner, Executive Vice President of Services at HEALTHCAREfirst. “I congratulate Heart to Heart Hospice on this achievement.”

Award criteria were based on Hospice CAHPS survey results for a one-year evaluation period and recipients were determined by performance on a set of 24 quality indicator measures. Scores were aggregated from all completed surveys and were compared on a question-by-question basis to a National Performance Score calculated from all hospices contained in the HEALTHCAREfirst’s Hospice CAHPS database.

Hospice Honors are awarded to hospice companies that scored above this national average on 20 of the evaluated questions, while Hospice Honors Elite recognizes those that scored above the national average on all 24 (100 percent).

Heart to Heart Hospice Founder and Chief Executive Officer Kelly Mitchell credits the staff and volunteers in Longview, San Antonio, San Marcos and Tyler. “Our dedicated team members believe in our mission of providing compassionate care. They work hard to make a difference in people’s lives, and they deserve this recognition,” said Mr. Mitchell.

About Heart to Heart Hospice

Heart to Heart Hospice, founded in 2003, is one of the largest private providers of hospice care in the United States. Headquartered in the Dallas-Fort Worth Metroplex, Heart to Heart provides a broad range of hospice services to patients with life-limiting illnesses across 35 locations in Texas, Michigan and Indiana. At Heart to Heart, we understand both the physical and emotional challenges for our patients and their loved ones and our care team is committed to providing them with what they need most: comfort, support and dignity. Learn more about Heart to Heart Hospice.

About HEALTHCAREfirst

HEALTHCAREfirst enables home health and hospice providers to streamline and optimize their business through cloud-based software solutions and services. Thousands of agencies use HEALTHCAREfirst’s CAHPS surveys, billing, coding and OASIS review, and advanced analytics services to create business efficiencies, simplify CMS compliance, expedite reimbursement and improve patient care. http://www.healthcarefirst.com

Share article on social media or email:

Cottonwood Group Extends $102 Million Loan to Refinance InterContinental® Houston – Medical Center


Cottonwood Group announced today the closing of a $102 million loan to refinance the InterContinental Houston – Medical Center. Cottonwood collaborated with Hana Alternative Asset Management to provide the financing to the luxury hotel developed by renowned Texas developer Medistar Corporation.

InterContinental Houston – Medical Center, which opened in March 2019, is a 22-story, 354-key hotel in the thriving Texas Medical Center (“TMC”) of Houston, Texas. The TMC is the largest medical complex in the world, with over 50 million square feet across 290 buildings, 21 hospitals, and 1,345 acres. It is also home to Texas Children’s Hospital, the world’s largest children’s hospital and MD Anderson Cancer Center, the world’s largest cancer hospital.

Located at 6750 Main Street, InterContinental Houston – Medical Center is the first full-service luxury hotel delivered in the TMC in several decades. Welcoming business and transient guests to the TMC ecosystem, the hotel features a high-end food and beverage offering, lobby bar, outdoor pool, state-of-the-art fitness center, workstations, and over 11,000 square feet of meeting and ballroom space. Unique to the hotel is its concierge medical clinic, which offers two private examination rooms and provides unparalleled on-site convenience and privacy.

“We are delighted to partner again with Hana Alternative Asset Management, after their investment in Cottonwood’s EchelonSeaport™ development in Boston, MA, to provide this transitional financing to the newly constructed InterContinental Houston – Medical Center,” said Jeffrey Horowitz, Senior Vice President of Investments at Cottonwood Group. “We are proud to contribute to the success of this landmark project which will meet a critical need for guests visiting and doing business in the TMC and look forward to building a lasting relationship with Medistar as they continue to expand their presence in the area.”

Monzer Hourani, Founder and CEO of Medistar, said, “We developed InterContinental Houston – Medical Center to provide unmatched comfort and convenience for traveling patients, visiting family members, and the many companies, institutions and professionals that innovate, teach and heal every day at the world-renowned Texas Medical Center. Cottonwood understands our hotel’s position and opportunity in the unique TMC market and has been an exceptional partner to Medistar.”

About Cottonwood Group

Headquartered in Los Angeles with offices in Boston and New York, Cottonwood Group is a privately-held real estate asset management and development company with $3.0 billion in assets under management. Building on its entrepreneurial, private equity roots, Cottonwood Group combines in-house structured finance capabilities with their operational expertise to unlock the full value of real estate opportunities. Its structured finance and real estate teams include seasoned private equity, finance and real estate professionals with national and international expertise in acquisitions, asset management and development. In addition to Los Angeles, Boston and New York, the company also manages real estate assets in other gateway US cities including San Francisco, Seattle, Las Vegas and Phoenix.

Media Contact: Cottonwood Group

Solomon McCown & Company

Anna Rabin Direct: 617-695-9555 / Cell: 857-248-5098

arabin@solomonmccown.com

Share article on social media or email:

Relatient Expands Nextech Marketplace Partnership to Enable More Patient-Centered Engagement Solutions


Relatient the leader in patient engagement

“I am thrilled to expand our partner position with Nextech and to add the Relatient Patient Self-Scheduling & Waitlist and eRegistration & Check-In solutions to expand in their marketplace of only selected vendors, because we can do more for their customers,” said Michele Perry, CEO, Relatient.

Relatient, Inc., the top-rated patient engagement SaaS announced today an expansion of their partnership with Nextech Systems, a leading healthcare technology provider for specialty physician practices. Nextech’s network of clients can now access Relatient’s latest solutions for patient self-scheduling, an automated waitlist, and patient intake, all integrated with Nextech’s Practice Management software and built to address the growing expectations of patients as consumers.

With Relatient’s latest solutions, practices can automate data entry, reduce the use of paper registration forms, and cut the time spent scheduling appointments over the phone. Choosing Patient Self-Scheduling & Waitlist and eRegistration enables practices to empower patients to manage their care with user-friendly online and mobile tools. Patients can use their own devices or an in-office tablet or iPad® with Relatient’s applications. All Nextech customer specialties—Ophthalmology, Dermatology, Orthopedics and Plastic Surgery—will have the ability to rely on Relatient’s integrated, bidirectional platform to manage all patient communications through text, email, and voice, with built-in best practices, all compliant to HIPAA and TCPA regulations.

“We recognize that our customers represent a variety of specialties that require the latest choices in technology. Partnering with Relatient provides our clients access to a highly-rated, patient engagement platform that effectively services both patients and providers,” stated Wyn Partington, Nextech’s Chief Revenue Officer. “We are pleased to make Relatient’s innovative solutions available to our clients, helping them get the most from their data and use of Nextech.”

Integrating Nextech’s Practice Management with new solutions in Relatient’s next-generation platform enables specialty physician practices to increase productivity and revenue while continuing to deliver patient-centered care. These latest Relatient solutions have unique functionalities such as manual or automated approval options for patient requested appointments and customized intake forms designed to support unique workflows and clinical operations. The Relatient platform also uses bidirectional data flow to seamlessly interface with Nextech’s solutions and work for multilocation offices and providers of all sizes.

“I am thrilled to expand our partner position with Nextech and to add the Relatient Patient Self-Scheduling & Waitlist and eRegistration & Check-In solutions to expand in their marketplace of only selected vendors, because we can do more for their customers,” said Michele Perry, CEO, Relatient. “Relatient spent 2019 working with Nextech customers to reduce no-shows and relieve them of manual tasks in appointment communications. Now Relatient is helping practices to fill their schedules and improve patient registration and intake.”

Relatient offers a full patient engagement platform of solutions—including Patient Appointment Reminders, Surveys, Broadcast Messaging, 2-Way Chat & Secure Messaging, Self-Scheduling, and eRegistration & Check-In—using a mobile-first strategy to help Nextech customers streamline communications with patients and better manage the overall experience.

About Relatient

Relatient is an industry recognized, award-winning, SaaS-based patient engagement company that improves patient and provider communications for increased patient satisfaction and improved productivity. Relatient has engaged more than 25 million patients on behalf of U.S. providers, medical practices, hospitals, and health systems and annually delivers 120 million patient messages. Relatient’s platform integrates with more than 85 practice management and electronic health databases to stop the phone tag, eliminate bottlenecks, reduce no-shows, drive appointments, increase online reviews, get patient feedback, and speed patient payments, all while supporting health and care quality initiatives. Visit http://www.relatient.net, call 866-473-8160.

About Nextech

Nextech is the complete healthcare technology solution for specialty providers. Since 1997, Nextech has been focused on delivering intelligent, intuitive, integrated solutions that empower specialty physicians to maximize efficiency, optimize charting accuracy and increase overall practice profitability. Nextech services more than 7,000 physicians and over 50,000 office staff members in the clinical specialties of Ophthalmology, Dermatology, Orthopedics and Plastic Surgery. Learn more at http://www.nextech.com.

Share article on social media or email:

Mindray to Attend RSNA Scientific Assembly as Ultrasound Industry Footprint Continues to Grow


Mindray

Mindray, a global developer of innovative ultrasound solutions, will unveil a new product and highlight its flagship Resona 7 Ultrasound System at RSNA 2019.

From pediatric to geriatric, and vascular to radiology, Mindray’s comprehensive suite of ultrasound machines aligns with the clinical and financial goals of a diverse range of ultrasound practices. Visit exhibit #8121 at RSNA 2019 to see all that Mindray has to offer.

Mindray, a global leader in the development of ultrasound machines and technologies, will attend the Radiological Society of North America’s (RSNA) 105th Scientific Assembly and Annual Meeting, December 1–6, at McCormick Place in Chicago, exhibit #8121. While there, Mindray will unveil its newest product and highlight its diverse portfolio of radiological ultrasound solutions.

Through concentrated efforts to bring their ultrasound technologies to the forefront of the space, Mindray prepares to head to RSNA following a string of milestone successes. These include the sale of their 100th Resona 7 System in North America and a partnership with Cincinnati Children’s Hospital Medical Center, one of the top children’s hospitals in the United States, according to U.S. News and World Report 2019-2020.

“As a leading developer of healthcare technology, Mindray is continually pushing towards our vision of better healthcare for all,” said Maher Elhihi, Director of Marketing for Mindray North America Ultrasound. “As the pressure continues to mount for our partners to cut costs and improve outcomes, we come through with unique and innovative solutions that enable clinicians to remain at the cutting-edge of ultrasound imaging for years to come. Our Living Technology™ and five-year warranty offer investment protection and ensure that our partners will not be left behind. In today’s rapidly changing technological landscape, that is a powerful proposition to bring forward.”

The following systems will be highlighted in Mindray exhibit #8121 and feature live scanning throughout the meeting:


  • Powered by the industry’s first virtual beamforming architecture, ZONE Sonography® Technology+ (ZST+), the Resona 7 System creates a perfectly focused image every pixel, every frame, every time. From skin line to deepest depths (up to 40 cm), the Resona 7 System is ideal for general imaging, vascular, women’s imaging and pediatric applications.
  • Also powered by ZST+, the ZS3 System optimizes workflow with a new user interface design and enables premium clinical solutions, such as Acoustic Radiation Force Impulse (ARFI) Imaging and CEUS, in a highly portable system. The combination of premium performance and mobility is highly suited for demanding imaging environments.
  • The TE7 System features eSpacial Navi™, a 4D magnetic needle navigation technology, delivering enhanced needle visualization for improved physician confidence and patient safety during interventional procedures.

From pediatric to geriatric, and vascular to radiology, Mindray’s comprehensive product suite aligns with the clinical and financial goals of a diverse range of ultrasound practices. Visit exhibit #8121 at RSNA 2019 to see all that Mindray has to offer.

About Mindray

Mindray is a leading developer, manufacturer and supplier of medical device solutions and technologies used in healthcare facilities around the globe. We believe we can change lives by making the most advanced healthcare technology attainable for all. We do this by empowering healthcare professionals through innovative, high-value solutions that help create the next generation of life-saving tools across three primary business segments: patient monitoring and life support, in-vitro diagnostics, and medical imaging. Mindray maintains its global headquarters in Shenzhen, China; Mindray North America is headquartered in Mahwah, New Jersey. Our Ultrasound Innovation Center is located in San Jose, California, with additional facilities in major international markets around the world. For more information, please visit http://www.mindray.com.

Share article on social media or email:

Benchmark Named ‘Top Place to Work’ By The Boston Globe For 12th Straight Year


News Image

We believe that human connection has the power to transform lives, and it’s our stellar associates who support our residents and their families with their compassionate care and vibrant community experiences through which everyone can grow and thrive, says Chairman and CEO Tom Grape.

Benchmark Senior Living, a human connection company and leading provider of senior living services in the Northeast, today announced that it has been named one of the Top Places to Work for the 12th straight year in The Boston Globe’s 12th annual associate-based survey. It is one of only four companies to have made the list every year it has been published and is the only senior living organization on the list. Benchmark ranked number 11 in the “Largest Company” category.

“We are incredibly honored to be recognized by the Globe year after year for our rich company culture, and being on this list every year since its inception is something we are extremely proud of,” says Chairman and CEO Tom Grape. “We believe that human connection has the power to transform lives, and it’s our stellar associates who support our residents and their families with their compassionate care and vibrant community experiences through which everyone can grow and thrive. We are incredibly grateful for their service.”

Top Places to Work recognizes the most admired workplaces in Massachusetts as voted by the people who know them best, their associates. The survey measures associates’ opinions anonymously about their company’s direction, execution, connection, management, work, pay and benefits, and engagement.

“The companies that make our list are much more than just decent employers,” says Katie Johnston, the Globe’s Top Places to Work editor. “They make work fun, and they make their people feel cared for. Some of them even help employees realize dreams that have nothing to do with their jobs.”

In addition to a comprehensive benefits package, Benchmark offers a wide variety of associate incentives and recognition programs designed to sustain its award-winning culture, including Gratitude Grams; Service Champion and Compassionate Caregiver awards; and the Benchmark One Company Fund, a non-profit organization providing funding to associates in need.

Throughout its 12 years on the Globe’s prestigious list, Benchmark has appeared with some of New England’s most prominent companies, including Accenture, Akamai, Bright Horizons, Comcast, Harvard Pilgrim Health Care, Massachusetts General Hospital, TripAdvisor and Tufts Health Plan.

Benchmark has been named to FORTUNE magazine’s Best Workplaces for Aging Services list both years it has been published. In 2019, it moved up to the number 15 spot on the list of 50 large companies in the senior housing and care category, ranking number five among senior living companies with 50 or more communities. Throughout its nearly 23-year history, the company has been recognized as a top workplace by the Boston Business Journal, Connecticut Post, Hartford Courant and Hartford Business Journal, and as one of the healthiest employers by Boston Business Journal and Providence Business News.

# # #

About Benchmark Senior Living

Benchmark is a leading provider of senior living communities in the Northeast with nearly 6,500 associates and 61 communities. Founded in 1997 by Tom Grape, Benchmark offers independent living, assisted living, memory care and continuing care retirement communities in eight states. The company has been named to FORTUNE magazine’s Best Workplaces for Aging Services list both years it has been published. In 2019, it moved up to the number 15 spot on the list of 50 large companies in the senior housing and care category, ranking number five among senior living companies with 50 or more communities. The company has been named to The Boston Globe’s Top Places to Work list every year of the 12 years it has been published. It also has been consistently recognized as a top workplace by Boston Business Journal, Hartford Courant and Hartford Business Journal and as one of the healthiest employers by the Boston Business Journal, Providence Business News and Hartford Business Journal. Visit BenchmarkSeniorLiving.com for more information.

Share article on social media or email:

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development


DEA APPROVES THC SHIPMENT FOR DRUG DEVELOPMENT

“We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”

Most recently the FDA awarded MMJ International Holdings ″Orphan Drug Designation″ for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. MMJ is confident that their pharmaceutical drugs will bring much needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington’s Disease. “We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases,” said Duane Boise, CEO of MMJ International Holdings.”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.” Tim Moynahan the company chairman stated that “Patients in the MMJ International holdings clinical trials will receiv e gelatin capsules containing THC and CBD daily.”

MMJ International Holdings has several academic institutions preparing to study cannabis in Multiple Sclerosis and Huntington’s disease. “MMJ clinical trials will provide the necessary data to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking.” Tim Moynahan further stated that, “Ultimately, there’s so much interest in THC and CBD as a treatment modality, so MMJ will be providing the clinical research data necessary to prove patient dosing, safety, and efficacy.” MMJ International Holdings continues its process of scientific drug development and discovery by FDA protocol development processes, intellectual property portfolio and DEA regulatory manufacturing guidelines.

About MMJ International Holdings:

MMJ International Holdings has established a leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. MMJ is successfully developing several prescription medications derived from the cannabis plant for the treatment of spasticity and chorea due to multiple sclerosis and Huntington’s disease.

The company has a pipeline of additional clinical stage cannabinoid and other natural botanical product candidates for both orphan and non-orphan indications with a specific focus on neurological conditions.

For more information visit: http://www.mmjih.com

For media inquiries please contact:

Michael Sharp

561-627-9455

For Investment Opportunities:

MFS Capital Advisors

917-562-9610

SOURCE: MMJ International Holdings

Share article on social media or email:

Suzana Marku, Nurse Practitioner of Women’s Excellence, Earns NAMS Certification


News Image

Women’s Excellence is pleased to announce that Suzana Marku, Nurse Practitioner, has successfully met the criteria and has passed the examination necessary to become a NAMS Certified Menopause Practitioner (NCMP).

Founded in 1989, NAMS is North America’s leading nonprofit organization dedicated to improving health and quality of life through an understanding of menopause.

Those who hold the NCMP certification have demonstrated special interest and competency in the field of menopause. These include, physicians, physician assistants, nurse practitioners, nurse midwives, nurses, and pharmacists.

Women’s Excellence offers a comprehensive menopause program that is dedicated to helping women transition through menopause through symptom management and lifestyle modifications. Women’s Excellence’s goal is treating the whole person. All of their services reflect the comprehensive nature of their philosophies of treatment. Evaluation or standard laboratory data is important but they also employ in depth interpretation of symptoms, evaluation of a woman’s lifestyle, and physical examination to help to outline a patient’s goals for menopausal management.

“Specialists in understanding the art and science of bioidentical hormonal therapy, our Providers are able to diagnose, treat and improve your symptoms. We treat all women with menopausal symptoms and provide guidance to those in menopause who do not desire hormones or who cannot take hormones secondary to other medical conditions,” said Jonathan Zaidan, MD, President of Women’s Excellence.

Women’s Excellence in Menopause is a specialty area of the practice for women that have symptoms of menopause. The latest and newest treatment options to treat the ramifications are utilized including bio-identical hormones and non-hormonal therapies to help with the symptoms and sequelae of menopause. Women’s Excellence in Menopause providers are able to diagnose, treat and improve your symptoms.

To schedule an appointment, visit http://www.WomensExcellence.com.

Online Patient Support Specialists are available Monday through Friday from 8am-5pm to assist new, current, and prospective patients. The chat is located at the bottom right corner of your computer or mobile device screen at  http://www.WomensExcellence.com. During offline hours, all chats sent will be messaged directly to a Women’s Excellence team member. Offline messages will receive a response within 24 hours. Messages received during the weekend will be answered the next business week. Appointments can also be made at (248) 693-0543.

Women’s Excellence is the most comprehensive obstetric and gynecologic office in Michigan. Additionally, they specialize in menopause, weight control, bladder control, endometriosis, robotic surgery, oncology, and midwifery services. Women’s Excellence is committed to staying at the forefront of innovation with cutting edge technologies utilizing robotic surgery and minimally invasive surgical options when possible. The knowledgeable, compassionate physicians and healthcare providers of Women’s Excellence focus on patient-centered processes to deliver the highest quality of care. They are affiliated with most insurances. They offer seamless medical record access via a state-of-the-art patient portal and use the latest technology for record keeping and sharing, making the patient experience easier and more efficient. Women’s Excellence is taking new patients and is conveniently located throughout southeastern Michigan in Clarkston, Lake Orion, Lapeer, Rochester, Royal Oak, and West Bloomfield. For more information, visit http://www.WomensExcellence.com.

Share article on social media or email:

Georgetown Home Care Lowers Preventable Hospital Readmissions With Its Key Program


“What was more amazing was how the readmission rate went right back up when the pilot ended.” – Ruth Adonizio, Director of Readmission Reduction at Medstar Georgetown University Hospital

Georgetown Home Care (GHC) recently conducted a pilot program, now called the Key Program, with Medstar Georgetown University Hospital (no affiliation) that significantly lowered their preventable hospital readmission rate.

The pilot program targeted spinal surgery patients, and in two months was able to reduce the hospital’s preventable readmissions by 44% among this population. Georgetown Home Care has signed a contract with Medstar Georgetown University Hospital to continue and expand this program to more departments within the hospital for fiscal year 2020. Through this collaboration, GHC foresees a significant improvement in patient outcomes.

“It was amazing what a positive effect the GHC pilot program had on our readmission rates!” said Ruth Adonizio, Director of Readmission Reduction at Medstar Georgetown University Hospital. “What was more amazing was how the readmission rate went right back up when the pilot ended. This was a big reason we agreed to sign a contract to continue the program with GHC.”

Georgetown Home Care achieved these results by implementing a proprietary process that is the result of closely studying the widespread problem of preventable hospital readmissions and enabling better transitions to home. “Our partnership with Medstar Georgetown University Hospital produced outstanding results,” says John Bradshaw, President of Georgetown Home Care. “By working closely with hospital leadership, we were able to customize a repeatable process to help them lower their rate of readmission significantly. We couldn’t be happier with the results and our on-going partnership.” From an institutional perspective, GHC’s Key Program produces results in a more cost effective and easier way than if the hospital or facility were to try and recreate this in house.

GHC’s Key Program was designed to answer the question of “why do patients keep coming back here?” The Key Program is a proprietary program that provides Nurse Practitioners to make house calls following a transition home from the hospital. The Key Program gives physicians eyes and ears in the home in order to better understand the patient’s ability to recover and what makes some more successful than others at doing so.

As of November 2019, GHC’s Key Program is available to all hospitals and facilities in the DC metro area.

Share article on social media or email:

DuPont Reveals Enhanced Application and Innovation Center, Increased Production Capacity at CPhI India


News Image

In today’s pharma industry, you must do more than just provide quality ingredients to make an impact; you have to accompany formulators through a product’s entire lifecycle.

DuPont Nutrition & Biosciences has consistently advanced its customers forward by ensuring global access to indispensable ingredients and unmatched expertise. At CPhI India, Nov. 26-28, the company will showcase increased capacity on both fronts, in addition to several product innovations such as solubility-enhancing polymers and vegetarian capsule offerings.

DuPont experts will be available at stand 8.Q20 to discuss a wide range of developments, including updated R&D capabilities at the DuPont Knowledge Center (DKC) in Hyderabad, India. The site has been a hub of innovation in the Genome Valley district since it opened in 2008. With new investments, the DKC will become South Asia’s premier application development and innovation facility for oral dosage delivery solutions, direct compression and solubility enhancement, as well as probiotics and biosciences. Manufacturers in South Asia will have unprecedented access to capabilities such as spray drying, hot melt extrusion, compaction simulation and advanced analytical equipment, all of which can solve formulation challenges posed by poorly soluble drugs. DuPont’s ultimate goal in updating the DKC is to help its customers test, research, develop and improve products to make them better, safer and more accessible.

In addition, DuPont will unveil its increased capacity to produce METHOCEL™ Premium HPMC, which will now be manufactured in both Stade, Germany, and Midland, Michigan, U.S. The Stade-based facility will benefit customers in Europe and India, who can now expect shorter lead times for shipments, business continuity planning support, supply chain management and non-GMO labelling for pharmaceutical and nutraceutical markets.

Formulation and product experts will also be on hand to discuss DuPont’s industry-leading products and capabilities, which include:


  • Enhanced R&D capabilities to create solutions for any manufacturing need, including controlled, immediate and delayed release; solubility enhancement; and nutraceuticals.
  • A global state-of-the-art manufacturing network that meets stringent regulatory and quality requirements to ensure all excipients meet ever-evolving standards.
  • International regulatory expertise and local market insights that enable formulators to obtain faster registration approvals.
  • Leadership in quality and regulatory support, which encompasses QbD support, highlighting regulatory education and full-spectrum guidance for drug product filing with DuPont excipients.
  • An innovative ingredient portfolio that includes SeaGel®, a vegetarian capsule offering aimed at meeting demand for plant-based options; and Aquateric™ N100, a cutting-edge enteric coating made from Norwegian brown seaweed; along with HOWARU® premium probiotics, a comprehensive range of clinically documented strains supporting digestive health, immune health, and a range of other health benefits. A wide array of controlled and immediate release solutions will also be on display.

“In today’s pharma industry, you must do more than just provide quality ingredients to make an impact; you have to accompany formulators through a product’s entire lifecycle,” said Savindu Kudrigikar, Business Director, South Asia at DuPont Nutrition & Biosciences. “For us, that means investing in our ability to meet demand and to educate formulators around the world. It all comes down to granting our customers the resources they need to deliver on the promise of a healthier life.”

DuPont now also offers a 70-year presence in silicone-based technology through the legacy of Dow Corning brands and technical experts who have joined the company. Our solutions include pharmaceutical excipients for a safe and efficacious delivery of actives in transdermal and topical therapies, and we also improve the spreadability and sensory aesthetics of semi-solid forms, which can lead to greater comfort and compliance for patients.

As the market for high-quality topical solutions for medical conditions has grown, DuPont’s portfolio has responded with solutions that are designed to deliver the performance consumers expect and the regulatory compliance formulators need. DuPont also will feature our broad range of bio-pharma processing solutions to meet the stringent performance and regulatory requirements for silicone tubing and over-molded assemblies used in fluid transfer and the manufacturing of biologic drugs.

To learn more about DuPont’s expanded capacity, innovative research and global footprint, visit CPhI India stand 8.Q20 or pharma.dupont.com.

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandhealth.com or http://www.biosciences.dupont.com.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at http://www.dupont.com.

# # #

11/22/19

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Share article on social media or email: